First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC - Takeaway - MDSpire
From the Journals
Clinical Guidelines

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Share

  • 1

    Zongertinib is an oral, irreversible tyrosine kinase inhibitor.

  • 2

    The trial enrolled 74 patients with advanced HER2-mutant NSCLC.

  • 3

    Objective response rate was 76%, with a median duration of 15.2 months.

  • 4

    Median progression-free survival reached 14.4 months.

  • 5

    Low-grade treatment-related adverse events affected 91% of patients.

  • 6

    Intracranial response rate in cohort 4 was 47% with 8.2 months progression-free survival.

  • 7

    The study provides insights into potential targets for HER2-mutant lung cancer treatment.

Original Source(s)

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

  • by Matthew Stenger

  • April 22, 2026

Related Content

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min